Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plast...
Uložené v:
| Vydané v: | Current controlled trials in cardiovascular medicine Ročník 20; číslo 1; s. 191 - 10 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
03.04.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1745-6215, 1745-6215 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer’s disease compared to those who are receiving placebo.
Methods/design
ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer’s dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in
z
scores for clinical and cognitive measures (Alzheimer’s Disease Assessment Scale—Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer’s Disease Cooperative Study—Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group.
Discussion
Alzheimer’s disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer’s treatment.
Trial registration
ClinicalTrials.gov,
NCT01843075
. Registration 30 April 2013. |
|---|---|
| AbstractList | Background
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer’s disease compared to those who are receiving placebo.
Methods/design
ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer’s dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in
z
scores for clinical and cognitive measures (Alzheimer’s Disease Assessment Scale—Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer’s Disease Cooperative Study—Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group.
Discussion
Alzheimer’s disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer’s treatment.
Trial registration
ClinicalTrials.gov,
NCT01843075
. Registration 30 April 2013. Abstract Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer’s disease compared to those who are receiving placebo. Methods/design ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer’s dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer’s Disease Assessment Scale—Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer’s Disease Cooperative Study—Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. Discussion Alzheimer’s disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer’s treatment. Trial registration ClinicalTrials.gov, NCT01843075. Registration 30 April 2013. BackgroundLiraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer’s disease compared to those who are receiving placebo.Methods/designELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer’s dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer’s Disease Assessment Scale—Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer’s Disease Cooperative Study—Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group.DiscussionAlzheimer’s disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer’s treatment.Trial registrationClinicalTrials.gov, NCT01843075. Registration 30 April 2013. Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo.BACKGROUNDLiraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo.ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale-Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study-Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group.METHODS/DESIGNELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale-Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study-Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group.Alzheimer's disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer's treatment.DISCUSSIONAlzheimer's disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer's treatment.ClinicalTrials.gov, NCT01843075 . Registration 30 April 2013.TRIAL REGISTRATIONClinicalTrials.gov, NCT01843075 . Registration 30 April 2013. Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo. ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale--Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study--Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. Alzheimer's disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer's treatment. Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo. ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale-Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study-Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. Alzheimer's disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer's treatment. ClinicalTrials.gov, NCT01843075 . Registration 30 April 2013. Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo. Methods/design ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale--Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study--Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. Discussion Alzheimer's disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer's treatment. Trial registration ClinicalTrials.gov, NCT01843075. Registration 30 April 2013. Keywords: Alzheimer's disease, Dementia, Randomised controlled trial, Liraglutide, Cerebral glucose metabolic rate |
| ArticleNumber | 191 |
| Audience | Academic |
| Author | Knight, Lucy Karim, Salman Junaid, Kehinde Lawrence, Robert Ridha, Basil H. Walker, Zuzana Edison, Paul Donaldson, Andrew Brooks, David J. Frangou, Eleni Busza, Gail Tadros, George Ritchie, Craig Underwood, Ben R. Malik, Naghma Love, Sharon B. Kshemendran, Sajeev Harrison, John Prasanna, Aparna Koranteng, Paul Thacker, Simon Bannister, Carol Mate, Vandana Passmore, Anthony Peter Nilforooshan, Ramin Femminella, Grazia Daniela Coulthard, Elizabeth Ballard, Clive McFarlane, Brady Russell, Gregor Holmes, Clive Archer, Hilary McGuinness, Bernadette Macharouthu, Ajay |
| Author_xml | – sequence: 1 givenname: Grazia Daniela surname: Femminella fullname: Femminella, Grazia Daniela organization: Department of Medicine, Imperial College London – sequence: 2 givenname: Eleni surname: Frangou fullname: Frangou, Eleni organization: Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford – sequence: 3 givenname: Sharon B. surname: Love fullname: Love, Sharon B. organization: Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford – sequence: 4 givenname: Gail surname: Busza fullname: Busza, Gail organization: Department of Medicine, Imperial College London – sequence: 5 givenname: Clive surname: Holmes fullname: Holmes, Clive organization: Southern Health NHS Foundation Trust – sequence: 6 givenname: Craig surname: Ritchie fullname: Ritchie, Craig organization: Department of Medicine, Imperial College London – sequence: 7 givenname: Robert surname: Lawrence fullname: Lawrence, Robert organization: SW London and St George’s Mental Health Trust – sequence: 8 givenname: Brady surname: McFarlane fullname: McFarlane, Brady organization: Southern Health NHS Foundation Trust – sequence: 9 givenname: George surname: Tadros fullname: Tadros, George organization: Aston Medical school, Aston University – sequence: 10 givenname: Basil H. surname: Ridha fullname: Ridha, Basil H. organization: Brighton and Sussex University Hospitals NHS Trust – sequence: 11 givenname: Carol surname: Bannister fullname: Bannister, Carol organization: South London and Maudsley NHS Foundation Trust – sequence: 12 givenname: Zuzana surname: Walker fullname: Walker, Zuzana organization: University College London and Essex Partnership University NHS Foundation Trust – sequence: 13 givenname: Hilary surname: Archer fullname: Archer, Hilary organization: North Bristol NHS Trust – sequence: 14 givenname: Elizabeth surname: Coulthard fullname: Coulthard, Elizabeth organization: North Bristol NHS Trust – sequence: 15 givenname: Ben R. surname: Underwood fullname: Underwood, Ben R. organization: Cambridgeshire and Peterborough NHS Foundation Trust – sequence: 16 givenname: Aparna surname: Prasanna fullname: Prasanna, Aparna organization: Black Country Partnership NHS Foundation Trust – sequence: 17 givenname: Paul surname: Koranteng fullname: Koranteng, Paul organization: Northamptonshire Healthcare NHS Foundation Trust – sequence: 18 givenname: Salman surname: Karim fullname: Karim, Salman organization: Lancashire Care NHS Foundation Trust – sequence: 19 givenname: Kehinde surname: Junaid fullname: Junaid, Kehinde organization: Nottinghamshire Healthcare NHS Foundation Trust – sequence: 20 givenname: Bernadette surname: McGuinness fullname: McGuinness, Bernadette organization: Centre for Public Health, Queen’s University Belfast – sequence: 21 givenname: Ramin surname: Nilforooshan fullname: Nilforooshan, Ramin organization: Surrey and Borders Partnership NHS Foundation Trust – sequence: 22 givenname: Ajay surname: Macharouthu fullname: Macharouthu, Ajay organization: NHS Ayrshire and Arran – sequence: 23 givenname: Andrew surname: Donaldson fullname: Donaldson, Andrew organization: NHS Lanarkshire – sequence: 24 givenname: Simon surname: Thacker fullname: Thacker, Simon organization: Derbyshire Healthcare NHS Foundation Trust – sequence: 25 givenname: Gregor surname: Russell fullname: Russell, Gregor organization: Bradford District Care NHS Foundation Trust – sequence: 26 givenname: Naghma surname: Malik fullname: Malik, Naghma organization: 5 Boroughs Partnership NHS Foundation Trust – sequence: 27 givenname: Vandana surname: Mate fullname: Mate, Vandana organization: Cornwall Partnership NHS Foundation Trust – sequence: 28 givenname: Lucy surname: Knight fullname: Knight, Lucy organization: Somerset Partnership NHS Foundation Trust – sequence: 29 givenname: Sajeev surname: Kshemendran fullname: Kshemendran, Sajeev organization: South Staffordshire and Shropshire Healthcare NHS Foundation Trust – sequence: 30 givenname: John surname: Harrison fullname: Harrison, John organization: Alzheimer Center VUmc Amsterdam, Institute of Psychiatry, Psychology & Neuroscience King’s College London – sequence: 31 givenname: David J. surname: Brooks fullname: Brooks, David J. organization: Department of Medicine, Imperial College London, Newcastle University – sequence: 32 givenname: Anthony Peter surname: Passmore fullname: Passmore, Anthony Peter organization: Centre for Public Health, Queen’s University Belfast – sequence: 33 givenname: Clive surname: Ballard fullname: Ballard, Clive organization: South London and Maudsley NHS Foundation Trust – sequence: 34 givenname: Paul orcidid: 0000-0002-6551-2002 surname: Edison fullname: Edison, Paul email: paul.edison@imperial.ac.uk organization: Department of Medicine, Imperial College London, School of Medicine, College of Biomedical and Life sciences, Cardiff University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30944040$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNURH_gAdggS2zKIsWOnR-zQBqVoVQaCRawthz7OuORJy52MmpZ8RRIvB5PgqdpaacC5IUd-zsnuveew2yv9z1k2XOCTwhpqteRUFzRHBOe06Lk-eWj7IDUrMyrgpR798772WGMK4wZ5ZQ9yfYp5oxhhg-yH_ONdKMcbN-hYQkIjAE1ROTN9WfvN-DQ2eJTTpDspfPdCMjZIDs3DlYDsj2auW9LsGsIv77_jEjbCDLCGxSHUV-hi-AHr7xDxgckUZC99uuEaKR8PwTvXDoOwUqHjueL2btJ9upp9thIF-HZzX6UfXk__3z6IV98PDs_nS1yVWE65HVdcsxKipnGtOFKFabBnBqQ1LSGG9NQrmjFS9aCNrrGrcZtUWkODBvMWnqUnU--2suVuAh2LcOV8NKK6wsfOiHDYJUDQSWG1Le21bpihChe16BVq1VRK1kzmrzeTl4XY7tOT5Dqk27HdPelt0vR-Y2oGGsKUiWD4xuD4L-OEAeROqXAOdmDH6MoCkwJrVldJPTlA3Tlx5AGlKial9sx4_KO6mQqwPbGp_-qramYlQ2hrCQNS9TJX6i0NKxtmhIYm-53BC_uF_qnwttUJaCeABV8jAGMUHZIGdtOXFonCBbb_IopvyLlV2zzKy6TkjxQ3pr_T1NMmpjYvoNw14t_i34DWlsEDQ |
| CitedBy_id | crossref_primary_10_1016_j_biopha_2024_117771 crossref_primary_10_3390_ijms232415811 crossref_primary_10_3233_JAD_230326 crossref_primary_10_3390_ijms23010548 crossref_primary_10_1016_j_arr_2021_101447 crossref_primary_10_1016_j_ejphar_2022_175439 crossref_primary_10_3389_fnagi_2021_741923 crossref_primary_10_1016_j_mad_2023_111898 crossref_primary_10_1007_s11064_021_03442_7 crossref_primary_10_1186_s13195_021_00853_0 crossref_primary_10_1016_j_molmed_2023_09_005 crossref_primary_10_3390_ijms21051746 crossref_primary_10_1016_j_ijbiomac_2022_11_031 crossref_primary_10_1111_cns_13791 crossref_primary_10_1186_s40001_025_02400_1 crossref_primary_10_1371_journal_pone_0261696 crossref_primary_10_2147_DDDT_S348055 crossref_primary_10_1016_j_apsb_2022_01_011 crossref_primary_10_1007_s11095_021_03100_1 crossref_primary_10_1016_j_jdiacomp_2023_108629 crossref_primary_10_2174_0115748855307998240529063710 crossref_primary_10_1007_s00424_024_02933_0 crossref_primary_10_1002_hsr2_71065 crossref_primary_10_3389_fnins_2021_687157 crossref_primary_10_1080_10408363_2025_2533860 crossref_primary_10_1016_j_addr_2022_114537 crossref_primary_10_3390_pharmaceutics17081036 crossref_primary_10_3390_ijms252211955 crossref_primary_10_1016_j_arr_2023_101979 crossref_primary_10_3389_fnins_2022_824054 crossref_primary_10_4103_1673_5374_389626 crossref_primary_10_1002_alz_13678 crossref_primary_10_1016_j_arr_2024_102481 crossref_primary_10_1097_ANA_0000000000000985 crossref_primary_10_1007_s00115_025_01813_x crossref_primary_10_7759_cureus_72080 crossref_primary_10_1007_s11064_023_04093_6 crossref_primary_10_1186_s13195_021_00784_w crossref_primary_10_1186_s13195_022_01103_7 crossref_primary_10_1016_j_phrs_2019_104611 crossref_primary_10_3390_ijms241411301 crossref_primary_10_3233_JAD_210612 crossref_primary_10_1002_brb3_1577 crossref_primary_10_1016_j_ncl_2024_03_003 crossref_primary_10_3233_JAD_240069 crossref_primary_10_1016_j_arr_2021_101462 crossref_primary_10_1111_bph_15683 crossref_primary_10_3389_fcell_2022_950623 crossref_primary_10_1007_s11892_025_01583_5 crossref_primary_10_1080_13543784_2022_2022122 crossref_primary_10_1111_jne_12959 crossref_primary_10_1002_alz_70621 crossref_primary_10_3389_fnins_2022_970925 crossref_primary_10_1016_j_bcp_2023_115831 crossref_primary_10_3389_fmolb_2025_1622186 crossref_primary_10_3233_ADR_230181 crossref_primary_10_3390_cells11132023 crossref_primary_10_33483_jfpau_1487011 crossref_primary_10_1016_j_lfs_2023_121983 crossref_primary_10_3389_fendo_2021_689678 crossref_primary_10_1111_jne_13074 crossref_primary_10_3390_ijms23179583 crossref_primary_10_3390_biology11030382 crossref_primary_10_5604_01_3001_0014_9532 crossref_primary_10_3390_antiox9020128 crossref_primary_10_1089_ars_2020_8070 crossref_primary_10_12688_f1000research_157890_2 crossref_primary_10_3390_molecules30051011 crossref_primary_10_12688_f1000research_157890_1 crossref_primary_10_3389_fphar_2025_1675552 crossref_primary_10_1016_j_cca_2022_12_016 crossref_primary_10_1016_j_npep_2022_102296 crossref_primary_10_1038_s41380_019_0542_x crossref_primary_10_1016_j_ejphar_2025_177979 crossref_primary_10_1016_j_npep_2025_102559 crossref_primary_10_1155_2022_9148650 crossref_primary_10_1016_j_lfs_2020_118645 crossref_primary_10_3390_ijms23169305 crossref_primary_10_3390_ijms23073785 crossref_primary_10_70749_ijbr_v3i3_715 crossref_primary_10_3390_ijms26188926 crossref_primary_10_1007_s13205_021_02738_3 crossref_primary_10_1007_s00415_021_10790_5 crossref_primary_10_3389_fendo_2022_874007 crossref_primary_10_3390_cimb46010021 crossref_primary_10_3390_metabo15030159 crossref_primary_10_3390_ijms22158208 crossref_primary_10_3389_fnsyn_2022_955258 crossref_primary_10_3233_JAD_210080 crossref_primary_10_1136_jnnp_2023_332661 crossref_primary_10_1016_j_phrs_2022_106358 crossref_primary_10_1007_s12149_020_01540_0 crossref_primary_10_1080_14728222_2022_2079492 crossref_primary_10_3389_fphys_2021_825816 crossref_primary_10_1016_j_neubiorev_2022_104642 crossref_primary_10_1111_bph_15508 crossref_primary_10_1111_febs_16177 crossref_primary_10_1186_s13063_020_04608_4 crossref_primary_10_1016_j_trecan_2025_02_006 crossref_primary_10_1016_j_molmet_2020_101102 crossref_primary_10_3390_ijms241411450 crossref_primary_10_3233_JAD_200049 crossref_primary_10_1227_neuprac_0000000000000098 crossref_primary_10_1136_bjophthalmol_2021_319232 crossref_primary_10_1038_s41380_022_01792_4 crossref_primary_10_1177_20420188231222367 crossref_primary_10_3390_biomedicines11113035 crossref_primary_10_3390_cimb46030130 crossref_primary_10_1111_dom_15216 crossref_primary_10_1136_bmjdrc_2021_002705 crossref_primary_10_1016_j_molmet_2019_09_010 crossref_primary_10_1159_000510677 crossref_primary_10_1016_j_jmb_2019_08_009 crossref_primary_10_1111_ejn_15619 crossref_primary_10_1080_17460441_2020_1674808 crossref_primary_10_1007_s43440_021_00293_5 crossref_primary_10_1016_j_pharmthera_2022_108270 crossref_primary_10_1097_01_NT_0000742020_38028_1d crossref_primary_10_3389_fnins_2022_937663 crossref_primary_10_1016_j_ejphar_2023_176117 crossref_primary_10_3389_fnmol_2020_00151 crossref_primary_10_3390_ijms241512486 crossref_primary_10_1136_jnnp_2024_335593 crossref_primary_10_1016_j_pharmthera_2022_108277 crossref_primary_10_3390_antiox10081257 crossref_primary_10_1016_j_tem_2025_07_003 crossref_primary_10_1038_s41366_020_0535_5 crossref_primary_10_3389_fnagi_2023_1122300 crossref_primary_10_1080_13543784_2020_1795127 crossref_primary_10_3390_biomedicines10040778 crossref_primary_10_3390_ijms26083905 crossref_primary_10_1080_13543784_2020_1738383 crossref_primary_10_3389_fnagi_2025_1601602 crossref_primary_10_1155_2023_7427136 crossref_primary_10_3390_cells13010065 crossref_primary_10_3390_ijms23020739 crossref_primary_10_1016_j_neubiorev_2022_104654 crossref_primary_10_1016_j_neubiorev_2022_104896 |
| Cites_doi | 10.1111/j.1530-0277.2007.00450.x 10.1124/jpet.300.3.958 10.1172/JCI59903 10.1111/j.1460-9568.1995.tb00650.x 10.1017/S0317167100005552 10.1016/j.jalz.2018.02.018 10.1212/01.WNL.0000265401.62434.36 10.7326/M18-1569 10.1016/S0031-9384(04)00348-8 10.1016/j.ejphar.2004.02.045 10.1074/jbc.M610390200 10.1097/MED.0b013e32825ea2ba 10.1111/dom.13373 10.1016/j.neurobiolaging.2008.04.002 10.1038/nm919 10.1097/00002093-199700112-00005 10.1515/REVNEURO.2005.16.3.181 10.2174/1567205054367892 10.1016/j.neurobiolaging.2010.1002.1014 10.1016/j.brainresrev.2007.09.001 10.1016/j.abb.2004.05.005 10.1097/WNR.0b013e32832fbf14 10.1016/j.ejphar.2016.04.052 10.1016/j.ejphar.2004.02.048 10.1523/JNEUROSCI.0529-11.2011 10.1210/endo.141.12.7806 10.3233/JAD-2008-13309 10.1111/j.1742-1241.2010.02498.x 10.1016/j.ejphar.2004.02.047 10.1111/j.1463-1326.2009.01075.x 10.1002/jnr.10611 10.1212/WNL.0b013e3181ffe4f6 10.1016/j.jalz.2011.11.002 10.1136/bmj.c332 10.1002/gps.2089 10.1016/j.ejphar.2004.02.049 10.1016/S1474-4422(07)70178-3 10.1016/j.neurobiolaging.2009.07.002 10.2337/db07-0171 10.1002/jnr.22565 10.1007/s40262-015-0343-6 10.3389/fnagi.2016.00108 10.1111/dom.12012 10.1016/j.ejphar.2004.02.050 10.1186/alzrt269 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. The Author(s). 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: The Author(s). 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-019-3259-x |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_3a0e309bbdd6411c977edcbdc27ca743 PMC6448216 A581345184 30944040 10_1186_s13063_019_3259_x |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | United Kingdom |
| GeographicLocations_xml | – name: United Kingdom |
| GrantInformation_xml | – fundername: Van Geest Foundation – fundername: Novo Nordisk UK Research Foundation funderid: http://dx.doi.org/10.13039/501100000329 – fundername: Alzheimer's Drug Discovery Foundation funderid: http://dx.doi.org/10.13039/100002565 – fundername: Alzheimer's Society funderid: http://dx.doi.org/10.13039/501100000320 – fundername: Medical Research Council grantid: G84/6523 – fundername: ; |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-7759045304d0389cc2f8093fea3fbf9ff839c36954bedfd70bd0b26d9e40f04b3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 159 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000467701300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1745-6215 |
| IngestDate | Fri Oct 03 12:45:28 EDT 2025 Tue Nov 04 01:55:02 EST 2025 Thu Sep 04 18:50:12 EDT 2025 Sun Oct 19 01:26:06 EDT 2025 Tue Nov 11 10:07:52 EST 2025 Tue Nov 04 17:19:05 EST 2025 Mon Jul 21 06:02:39 EDT 2025 Sat Nov 29 06:09:25 EST 2025 Tue Nov 18 21:13:26 EST 2025 Sat Sep 06 07:26:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cerebral glucose metabolic rate Alzheimer’s disease Liraglutide Randomised controlled trial Dementia |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-7759045304d0389cc2f8093fea3fbf9ff839c36954bedfd70bd0b26d9e40f04b3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-6551-2002 |
| OpenAccessLink | https://doaj.org/article/3a0e309bbdd6411c977edcbdc27ca743 |
| PMID | 30944040 |
| PQID | 2795393405 |
| PQPubID | 44365 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3a0e309bbdd6411c977edcbdc27ca743 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6448216 proquest_miscellaneous_2203137472 proquest_journals_2795393405 gale_infotracmisc_A581345184 gale_infotracacademiconefile_A581345184 pubmed_primary_30944040 crossref_citationtrail_10_1186_s13063_019_3259_x crossref_primary_10_1186_s13063_019_3259_x springer_journals_10_1186_s13063_019_3259_x |
| PublicationCentury | 2000 |
| PublicationDate | 2019-04-03 |
| PublicationDateYYYYMMDD | 2019-04-03 |
| PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-03 day: 03 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | M Prince (3259_CR1) 2015 JP Frias (3259_CR25) 2007; 14 ZG Li (3259_CR13) 2007; 56 R Perfetti (3259_CR30) 2000; 141 E Carro (3259_CR14) 2004; 490 3259_CR23 CR Jack Jr (3259_CR49) 2018; 14 M Gejl (3259_CR4) 2016; 8 WQ Zhao (3259_CR16) 2004; 490 LV Jacobsen (3259_CR44) 2016; 55 L Li (3259_CR10) 2007; 56 L Blonde (3259_CR22) 2009; 11 R Goke (3259_CR28) 1995; 7 A Hamilton (3259_CR37) 2011; 89 M Townsend (3259_CR36) 2007; 282 MJ During (3259_CR33) 2003; 9 A Hamilton (3259_CR29) 2009; 20 KF Schulz (3259_CR48) 2010; 340 AM Moloney (3259_CR6) 2010; 31 OI Okereke (3259_CR18) 2008; 24 A Vella (3259_CR40) 2002; 45 M Nauck (3259_CR24) 2013; 15 D Galasko (3259_CR43) 1997; 11 SM Landau (3259_CR46) 2011; 32 T Perry (3259_CR31) 2002; 300 A Kirk (3259_CR41) 2007; 34 K Talbot (3259_CR39) 2012; 122 MA Reger (3259_CR19) 2008; 70 JM Cedarbaum (3259_CR42) 2013; 9 LD Baker (3259_CR20) 2010; 68 B Dubois (3259_CR50) 2007; 6 JL Cummings (3259_CR2) 2014; 6 B Cao (3259_CR21) 2018; 20 C Holscher (3259_CR8) 2005; 16 AC Cohen (3259_CR11) 2007; 31 3259_CR45 P van Dam (3259_CR12) 2004; 490 S Hoyer (3259_CR9) 2004; 490 Mawdsleys (3259_CR47) 2017 BD Green (3259_CR26) 2004; 428 L Qi (3259_CR3) 2016; 783 P McClean (3259_CR38) 2011; 31 MA Reger (3259_CR17) 2008; 13 EM Schrijvers (3259_CR5) 2010; 75 3259_CR35 3259_CR34 GS Watson (3259_CR15) 2004; 490 U Stockhorst (3259_CR7) 2004; 83 T Perry (3259_CR32) 2003; 72 T Perry (3259_CR27) 2005; 2 32684162 - Trials. 2020 Jul 19;21(1):660. doi: 10.1186/s13063-020-04608-4. |
| References_xml | – volume: 31 start-page: 1558 issue: 9 year: 2007 ident: 3259_CR11 publication-title: Alcohol Clin Exp Res doi: 10.1111/j.1530-0277.2007.00450.x – volume: 300 start-page: 958 issue: 3 year: 2002 ident: 3259_CR31 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.300.3.958 – volume: 122 start-page: 1316 issue: 4 year: 2012 ident: 3259_CR39 publication-title: J Clin Invest doi: 10.1172/JCI59903 – volume: 7 start-page: 2294 issue: 11 year: 1995 ident: 3259_CR28 publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.1995.tb00650.x – volume: 34 start-page: S42 issue: Suppl 1 year: 2007 ident: 3259_CR41 publication-title: Can J Neurol Sci doi: 10.1017/S0317167100005552 – volume: 14 start-page: 535 issue: 4 year: 2018 ident: 3259_CR49 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2018.02.018 – volume: 70 start-page: 440 issue: 6 year: 2008 ident: 3259_CR19 publication-title: Neurology doi: 10.1212/01.WNL.0000265401.62434.36 – ident: 3259_CR23 doi: 10.7326/M18-1569 – volume: 83 start-page: 47 issue: 1 year: 2004 ident: 3259_CR7 publication-title: Physiol Behav doi: 10.1016/S0031-9384(04)00348-8 – volume: 490 start-page: 71 issue: 490 year: 2004 ident: 3259_CR16 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2004.02.045 – volume: 282 start-page: 33305 issue: 46 year: 2007 ident: 3259_CR36 publication-title: J Biol Chem doi: 10.1074/jbc.M610390200 – volume: 14 start-page: 269 issue: 4 year: 2007 ident: 3259_CR25 publication-title: Curr Opin Endocrinol Diabetes Obes doi: 10.1097/MED.0b013e32825ea2ba – volume: 20 start-page: 2467 issue: 10 year: 2018 ident: 3259_CR21 publication-title: Diabetes Obes Metab doi: 10.1111/dom.13373 – volume: 31 start-page: 224 issue: 2 year: 2010 ident: 3259_CR6 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2008.04.002 – volume: 9 start-page: 1173 issue: 9 year: 2003 ident: 3259_CR33 publication-title: Nat Med doi: 10.1038/nm919 – volume: 11 start-page: S33 issue: Suppl 2 year: 1997 ident: 3259_CR43 publication-title: Alzheimer Dis Assoc Disord doi: 10.1097/00002093-199700112-00005 – volume: 16 start-page: 181 issue: 3 year: 2005 ident: 3259_CR8 publication-title: Rev Neurosci doi: 10.1515/REVNEURO.2005.16.3.181 – volume: 2 start-page: 377 issue: 3 year: 2005 ident: 3259_CR27 publication-title: Curr Alzheimer Res doi: 10.2174/1567205054367892 – ident: 3259_CR35 doi: 10.1016/j.neurobiolaging.2010.1002.1014 – volume: 56 start-page: 384 year: 2007 ident: 3259_CR10 publication-title: Brain Res Rev doi: 10.1016/j.brainresrev.2007.09.001 – volume-title: World Alzheimer Report 2015—the global impact of dementia: an analysis of prevalence, incidence, cost and trends year: 2015 ident: 3259_CR1 – volume: 428 start-page: 136 issue: 2 year: 2004 ident: 3259_CR26 publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2004.05.005 – volume: 20 start-page: 1161 year: 2009 ident: 3259_CR29 publication-title: Neuroreport doi: 10.1097/WNR.0b013e32832fbf14 – volume: 783 start-page: 23 year: 2016 ident: 3259_CR3 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2016.04.052 – volume: 490 start-page: 97 issue: 1–3 year: 2004 ident: 3259_CR15 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2004.02.048 – volume: 31 start-page: 6587 year: 2011 ident: 3259_CR38 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0529-11.2011 – volume: 141 start-page: 4600 issue: 12 year: 2000 ident: 3259_CR30 publication-title: Endocrinology doi: 10.1210/endo.141.12.7806 – ident: 3259_CR34 – volume: 13 start-page: 323 issue: 3 year: 2008 ident: 3259_CR17 publication-title: J Alzheimers Dis doi: 10.3233/JAD-2008-13309 – ident: 3259_CR45 doi: 10.1111/j.1742-1241.2010.02498.x – volume: 490 start-page: 87 issue: 1–3 year: 2004 ident: 3259_CR12 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2004.02.047 – volume: 11 start-page: 26 issue: Suppl 3 year: 2009 ident: 3259_CR22 publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2009.01075.x – volume-title: Pharmaceutical distributor, wholesale, healthcare year: 2017 ident: 3259_CR47 – volume: 72 start-page: 603 issue: 5 year: 2003 ident: 3259_CR32 publication-title: J Neurosci Res doi: 10.1002/jnr.10611 – volume: 75 start-page: 1982 issue: 22 year: 2010 ident: 3259_CR5 publication-title: Neurology doi: 10.1212/WNL.0b013e3181ffe4f6 – volume: 9 start-page: S45 issue: 1 Suppl year: 2013 ident: 3259_CR42 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.11.002 – volume: 340 start-page: c332 year: 2010 ident: 3259_CR48 publication-title: BMJ doi: 10.1136/bmj.c332 – volume: 24 start-page: 177 year: 2008 ident: 3259_CR18 publication-title: Int J Geriatr Psychiatry doi: 10.1002/gps.2089 – volume: 490 start-page: 115 issue: 1–3 year: 2004 ident: 3259_CR9 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2004.02.049 – volume: 6 start-page: 734 issue: 8 year: 2007 ident: 3259_CR50 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(07)70178-3 – volume: 32 start-page: 1207 issue: 7 year: 2011 ident: 3259_CR46 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2009.07.002 – volume: 56 start-page: 1817 issue: 7 year: 2007 ident: 3259_CR13 publication-title: Diabetes doi: 10.2337/db07-0171 – volume: 89 start-page: 481 issue: 4 year: 2011 ident: 3259_CR37 publication-title: J Neurosci Res doi: 10.1002/jnr.22565 – volume: 55 start-page: 657 issue: 6 year: 2016 ident: 3259_CR44 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-015-0343-6 – volume: 8 start-page: 108 year: 2016 ident: 3259_CR4 publication-title: Front Aging Neurosci doi: 10.3389/fnagi.2016.00108 – volume: 15 start-page: 204 issue: 3 year: 2013 ident: 3259_CR24 publication-title: Diabetes Obes Metab doi: 10.1111/dom.12012 – volume: 490 start-page: 127 issue: 1–3 year: 2004 ident: 3259_CR14 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2004.02.050 – volume: 6 start-page: 37 issue: 4 year: 2014 ident: 3259_CR2 publication-title: Alzheimers Res Ther doi: 10.1186/alzrt269 – volume: 68 start-page: 51 issue: 1 year: 2010 ident: 3259_CR20 publication-title: Arch Neurol – volume: 45 start-page: 1410 issue: 10 year: 2002 ident: 3259_CR40 publication-title: Diabetologia – reference: 32684162 - Trials. 2020 Jul 19;21(1):660. doi: 10.1186/s13063-020-04608-4. |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.5689828 |
| Snippet | Background
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic... Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of... Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic... BackgroundLiraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic... Abstract Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 191 |
| SubjectTerms | Activities of Daily Living Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer Disease - physiopathology Alzheimer Disease - psychology Alzheimer's disease Antidiabetics Apoptosis Batteries Biomarkers Biomedicine Brain Brain - drug effects Brain - metabolism Brain - physiopathology Brain research Care and treatment Cell growth Cerebral glucose metabolic rate Clinical trials Clinical Trials, Phase II as Topic Cognition & reasoning Cognition - drug effects Dementia Development and progression Diabetes Double-Blind Method Drug dosages Genetic engineering Glucagon Glucagon-Like Peptide-1 Receptor - metabolism Glucagon-Like Peptide-1 Receptor Agonists Glucose Glucose - metabolism Growth factors Health Sciences Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin Liraglutide Liraglutide - adverse effects Liraglutide - therapeutic use Medical research Medicine Medicine & Public Health Memory Memory - drug effects Metabolism Morbidity Multicenter Studies as Topic Neurons Neuroprotective Agents - adverse effects Neuroprotective Agents - therapeutic use Obesity Oligomers Peptides Phosphorylation Physiology Proteins Randomised controlled trial Randomized Controlled Trials as Topic Severity of Illness Index Statistics for Life Sciences Study Protocol Time Factors Tomography Treatment Outcome Type 2 diabetes United Kingdom |
| SummonAdditionalLinks | – databaseName: ProQuest Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELYgRYhLecNCQUZC4qVVvLbXu-aCAqSAlFY5ACona_3YNFK6W5K0qjjxK5D4e_wSxrtOyhbRE7cktiPP-vN4xjP7DUKPmeEpdZzHQsIy8CIVcW4ycFUYBXhQXbbE859H2e5uvrcnx-H16EVIq1zpxEZRt2zPPm8blHDf1sbfmPdpJlMmGVgbrw6_xr6GlI-1hoIaF9GGJ94iPbQx_rAz_rKOKmS54CGymeSivwD97aOYiYwZeAHxSedsaij8_1bUf5xUZ7Moz4RSmxNq--r_le0a2gyWKh600LqOLrjqBrq8E2LxN9GPYSAKryYYrEgcMkNwXTZfq_rYzfC70ThOcFG1V0R4Np0XE4916_C0woPZt303PXDzX99_LnCIFb3EDeUt9gwSNcAUg1mNCwxnqq0BlM7ikF4_g49N0RH8dDgavG2HPbuFPm0PP755H4cqD7ERhC3BvE8l2JWMcOvJ_oyhZU4kK13BSl3KsgQTzjAhU66dLW1GtCWaCisdJyXhmt1Gvaqu3F2EBTM5t7bQ3FleSKnBcyisoNrQDP5cRois1leZQIHuK3HMVOMK5UK1kFAACeUhoU4i9Hw95LDl_ziv82sPmnVHT93d_FDPJypoAsUK4hiRWlsreJIYMMABQ9rCHE0B9lyEnnjIKa9gYHKmCO9JgIieqksN0jxhPAXPPEJbnZ6wBqbbvEKbCoppoU7BFaFH62Y_0ifbVa4-gj7UE3qCn0kjdKfF-FokmLlnlCQRyjro78jcbamm-w1tub8JoImI0IvVPjmd1j8f6b3zhbiPrlC_f30qFdtCveX8yD1Al8zxcrqYPwz7_zdXPmw6 priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLbQgBAX9iUwICMhsSnCsR0n5lagA4cyGgkYzc2Kl3QilQS1nRHixK9A4u_xS3h2nEKGRYJbWz9XXj6_Je_lM0L3mOE5dZynQsI28CoXaWkKCFUYBXhQXffE8_uzYne3PDiQe_E97tVQ7T6kJIOmDse6FE9WoG19zjGTKQOfPQXH8XTuyWZ8iP5mf1C_YGAZj-nL33YbGaDA0_-rNv7JHJ0slTyRLw1maOfCf03gIjofvU486WFyCZ1y7WV09nXMq19BX6aR9LudY_AIcazywF0dvrbdsVvgl7O9NMNV2z_uwYtmWc09bq3DTYsni0-Hrnnvlt8-f13hmPd5igN9LfZsEB1ADoOLjCsM9tF2ADBncSyVX8DHcIEIfjCdTV703R5eRe92pm-fv0rjjQ2pEYStwVXPJfiIjHDrifuMoXVJJKtdxWpdy7oGd8wwIXOuna1tQbQlmgorHSc14ZpdQ1tt17obCAtmSm5tpbmzvJJSQxRQWUG1oQX8uUwQGbZRmUhn7m_VWKgQ1pRC9eutYL2VX2_1MUGPNl0-9FwefxN-5rGxEfQ03OGHbjlX8VQrVhHHiNTaWsGzzIAzDVDRFsZoKvDNEnTfI0t5ZQGDM1V85wGm6Gm31CQvM8ZziLITtD2ShD0w4-YBmyoqmZWihcw92kmeoLubZt_TF861rjsCGerJOSFmpAm63kN5MyUYuWeHJAkqRiAfzXnc0jaHgYLcR_U0Ewl6PED9x7D-uKQ3_0n6FjpH_VnxVVJsG22tl0fuNjpjjtfNanknnPnvVVlVkA priority: 102 providerName: Springer Nature |
| Title | Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study) |
| URI | https://link.springer.com/article/10.1186/s13063-019-3259-x https://www.ncbi.nlm.nih.gov/pubmed/30944040 https://www.proquest.com/docview/2795393405 https://www.proquest.com/docview/2203137472 https://pubmed.ncbi.nlm.nih.gov/PMC6448216 https://doaj.org/article/3a0e309bbdd6411c977edcbdc27ca743 |
| Volume | 20 |
| WOSCitedRecordID | wos000467701300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7X7 dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7RV dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: BENPR dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: PIMPY dateStart: 20000401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZgIMQL4k5gVEZC4qZoju1czFsHHSB1VVWg6p6s-JKtUkhQ200TT_wKJP4ev4TjxC3LEPDCS1TXdmT7fPY5p-f0M0KPmeYxtZyHiQAx8DxOwkyn4KowCvCgqmiJ56fDdDTKZjMxPnPVl8sJa-mB24XbYTmxjAiljEl4FGmwV6zRymia6hzUnzt9SSrWzlR7BoOWZdzHMKMs2VnCSe3ilZEIGdj74WlHCzVk_b8fyWd00vl8yXNB00YX7V1H17wRifvt4G-gC7a6ia7s-zD5LfRt4Dm8q0MMBh72SRu4LppiVZ_YEr8ZjsMI51X76w0u54v80MHQWDyvcL_8cmTnn-zix9fvS-zDOC9xw0aLHblDDQjCYPHiHIO6MzXgxRrsM99L-NjcB4KfDob91223Z7fRx73Bh1dvQ38BQ6gTwlZgeccCTD5GuHE8fFrTIiOCFTZnhSpEUYB1pVkiYq6sKUxKlCGKJkZYTgrCFbuDtqq6svcQTpjOuDG54tbwXAgFRn1uEqpAjvByESCyFojUnp3cXZJRysZLyRLZylCCDKWToTwN0PNNl88tNcffGu86KW8aOlbt5gvAmvRYk__CWoCeOIxIt_dhcDr3f2GAKToWLdmPs4jxGJzmAG13WoIMdLd6jTLpz4ylpKmIHW5JHKBHm2rX0-XBVbY-hjbUcW2CC0gDdLcF5WZKMHJH9kgClHbg2plzt6aaHzWM4s5Jp1ESoBdrYP8a1h-X9P7_WNIH6Cp129LlQrFttLVaHNuH6LI-Wc2Xix66mE6m7jlLm2fWQ5d2B6PxpNdsdyiN3-2PD6A0eT_9CRYXWYU |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VFgEX3o9AASOBKKCoie08jITQQrd01W21h4LKySS2s11pScpuWwonfgUSf4IfxS9hnHi3bBG99cBts3YiP74Zz3jGnwEeMsUjajj3Y4HTwLMo9lOVoKvCKMKD5kVDPP-um2xuptvbojcHPydnYWxa5UQn1opaV8rukS_TRERMMLQvXu5-8u2tUTa6OrlCo4HFuvnyGV228YvOCs7vI0pX21uv13x3q4Cv4oDtoTkZCbRj0I3XllxOKVqk6NYXJmNFXoiiQJNBsVhEPDe60EmQ6yCnsRaGB0XAc4bfPQMLHMEezMNCr7PRez-NWyRpzF3sNEzj5TGuEDZOGgqfoZ_hH86sfvUlAX8vBX-shcfzNI8Fa-s1cPXS_zZ6l-Gis7ZJqxGPKzBnyqtwbsPlE1yD721Hdl72CVrCxGW3kKqoH8vqwAzJm27PD0lWNttcZDgYZX0rr9qQQUlaw687ZvDRjH59-zEmLt71nNS0vcSyYFQoagRdA5IRtAt0hYJlNHFHBIb4s744hSy1u62V5rUn1-HtqYzKDZgvq9LcAhIzlXKts5wbzTMhcvR-Mh3TXNEEPy48CCYIksrRuNvbRIaydufSWDagkwg6aUEnDz14On1lt-EwOanyKwvLaUVLP17_UY360mkzybLAsEDkudYxD0OFTgSiNNfYRpWhTerBYwtqaZUkNk5l7qwHdtHSjclWlIaMR2HKPVicqYlzoGaLJ3iWTrmO5RGYPXgwLbZv2oTB0lT7WIdaUlL0lakHNxspmnYJW25ZMQMPkhn5munzbEk52Kmp1-1uBg1jD55NJPGoWf8c0tsnd-I-nF_b2ujKbmdz_Q5coFZb2NQwtgjze6N9cxfOqoO9wXh0z2kbAh9OW0R_AzQTviU |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VFlVceD8CBYwE4qWoie08jITQlt1C1WW1qgD1ZhLb2a60JGW3LYUTvwKJv8LP4ZcwTrxbtojeeuCWxHbkx8x4xjP-BuA-UzyihnM_FrgMPItiP1UJmiqMInnQvGiA5993k14v3d4W_QX4Ob0LY8MqpzKxFtS6UvaMfJUmImKCoX6xWriwiH57_cXuJ99mkLKe1mk6jYZENs2Xz2i-TZ5vtHGtH1C63nn78rXvMgz4Kg7YHqqWkUCdBk16bYHmlKJFiiZ-YTJW5IUoClQfFItFxHOjC50EuQ5yGmtheFAEPGf43zOwlDA0ehZhaa3T62_NfBhJGnPnRw3TeHWCu4X1mYbCZ2hz-IdzO2GdMODvbeGPffF4zOYxx229H65f-J9n8iKcd1o4aTVscwkWTHkZlt-4OIMr8L3jQNDLAUENmbioF1IV9WtZHZgRedXt-yHJyub4i4yG42xg-VgbMixJa_R1xww_mvGvbz8mxPnBnpEazpdYdIwKWZCgyUAygvqCrpDhjCbu6sAIH-uEKuRRp9tqN80eX4V3pzIr12CxrEpzA0jMVMq1znJuNM-EyNEqynRMc0UT_LnwIJhSk1QO3t1mGRnJ2sxLY9kQoEQClJYA5aEHT2ZNdhtsk5Mqr1kSnVW0sOT1h2o8kE7KSZYFhgUiz7WOeRgqNC6QYnONfVQZ6qoePLQELq3wxM6pzN0BwSFaGDLZitKQ8ShMuQcrczVxDdR88ZS2pRO6E3lE2B7cmxXbljaQsDTVPtahFqwUbWjqwfWGo2ZDwp5btMzAg2SO1-bGPF9SDndqSHZ7ykHD2IOnU6486tY_p_TmyYO4C8vIl7K70du8BeeoFRw2YoytwOLeeN_chrPqYG84Gd9xgofAh9Pm0N-rl8a_ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+the+effects+of+the+novel+GLP-1+analogue+liraglutide+in+Alzheimer%E2%80%99s+disease%3A+study+protocol+for+a+randomised+controlled+trial+%28ELAD+study%29&rft.jtitle=Trials&rft.au=Grazia+Daniela+Femminella&rft.au=Eleni+Frangou&rft.au=Sharon+B.+Love&rft.au=Gail+Busza&rft.date=2019-04-03&rft.pub=BMC&rft.eissn=1745-6215&rft.volume=20&rft.issue=1&rft.spage=1&rft.epage=10&rft_id=info:doi/10.1186%2Fs13063-019-3259-x&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_3a0e309bbdd6411c977edcbdc27ca743 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |